AbbVie (ABBV) shares are holding steady as investors assess the company’s ongoing performance following recent earnings. With key drugs still leading the portfolio, many are watching how AbbVie manages steady growth in a competitive sector.

See our latest analysis for AbbVie.

AbbVie’s share price has steadily climbed this year, with a year-to-date return of nearly 27%. The company’s recent updates have not slowed its momentum, as investor confidence continues to build. This is reflected in an impressive 1-year total shareholder return of almost 29% and a 5-year total return of 158%.

If biopharma momentum sparks your curiosity, it could be the perfect time to see what other healthcare leaders are achieving. See the full list for free.

With AbbVie trading near its price target and showing robust returns, investors are left to ponder whether the current valuation leaves room for upside or if the market is already accounting for future growth.

AbbVie’s last close price of $227.70 is below the most popular narrative’s fair value estimate of $243.55. This suggests that market sentiment sees potential for further upside, even as recent analyst revisions have edged higher. The prevailing perspective focuses on new product momentum and higher margin forecasts, pointing to a potential catalyst for the years ahead.

Advancements and strategic investments in neuroscience, including strong uptake of Vraylar, QULIPTA, Ubrelvy, and the emerging Parkinson's portfolio (such as VYALEV), align with growing demand for therapies addressing chronic neurological diseases in an aging population. This supports both revenue and long-term earnings stability.

Read the complete narrative.

Want to know what supports this target price? The narrative’s valuation incorporates expectations for sales growth, expanding profit margins, and a future earnings multiple that stands out among industry peers. Explore the forecasts and assumptions analysts use in these calculations, and consider whether the underlying numbers resonate with your perspective.

Result: Fair Value of $243.55 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ongoing patent expirations and increased regulatory scrutiny could put pressure on AbbVie's future earnings and challenge the current growth outlook.

Find out about the key risks to this AbbVie narrative.

If you see things differently, or want to dig into the figures on your own terms, it’s easy to shape your own story in just a few minutes. Do it your way.

A great starting point for your AbbVie research is our analysis highlighting 2 key rewards and 5 important warning signs that could impact your investment decision.

Strengthen your strategy with new opportunities. These market-leading trends are just a click away and you won't want to miss what savvy investors are tracking next.

Boost your long-term returns by tapping into steady, income-generating picks through 3%;elm:context_link;itc:0;sec:content-canvas\\" class=\\"link \\">these 15 dividend stocks with yields > 3% delivering yields above 3%.

Ride the next wave of innovation with these 25 AI penny stocks as artificial intelligence transforms industries and powers significant growth potential.

Capitalize on tech’s frontier and position yourself early within breakthrough companies driving the future of computing via these 28 quantum computing stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ABBV.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com